Finance

Lists
Q3 2026 earnings • released • EPS beat +166.67% • Revenue beat +3.62%
See results
PGEN:NASDAQ
Precigen Inc
$4.47
+5.92%
(+0.25) 1D
$4.44
-0.67% (-0.030)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PGEN...
Open
$4.32
High
$4.48
Low
$4.03
Mkt. cap
1.60B
Avg. vol.
6.73M
Volume
9.24M
52-wk high
$8.98
52-wk low
$3.04
EPS
-$1.10
Beta
1.01
Shares outstanding
358.55M
No. of employees
160
Open
$4.32
High
$4.48
Low
$4.03
Mkt. cap
1.60B
Avg. vol.
6.73M
Volume
9.24M
52-wk high
$8.98
52-wk low
$3.04
EPS
-$1.10
Beta
1.01
Shares outstanding
358.55M
No. of employees
160
News stories
From web sources and news partners
Profile
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. Wikipedia
About Precigen Inc
CEOHelen Sabzevari
Employees160
FoundedMay 21, 1998
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteprecigen.com
Analyst ratings
Based on 3 analysts giving stock ratings to PGEN in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for PGEN in the last 3 months.
Highest
Current $4.47
$18.00 (+302.68%)
Average
$14.00 (+213.20%)
Lowest
$12.00 (+168.46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$18.00
+302.7%
11/05/2026
Jason Butler
Citizens JMP
Buy
Maintained
$12.00
+168.5%
11/05/2026
Yuan Zhi
B. Riley Securities
Buy
Maintained
$12.00
+168.5%
10/27/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$0.08 / $0.03
+166.67%beat
Revenue / Est. (USD)
74.15M / 71.56M
+3.62%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
4.56M
23.25M
54.98M
74.15M
Cost of goods sold
8.59M
8.20M
10.09M
13.14M
Cost of revenue
8.59M
8.20M
10.09M
13.14M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17.64M
21.05M
22.25M
22.36M
Operating expense
17.64M
21.05M
22.25M
22.36M
Total operating expenses
26.23M
29.25M
32.34M
35.50M
Operating income
-21.67M
-5.99M
22.64M
38.65M
Other non operating income
60.00K
290.00K
16.00K
-11.00K
EBT including unusual items
-23.50M
-7.93M
20.07M
35.97M
EBT excluding unusual items
-23.50M
-7.93M
20.07M
35.97M
Income tax expense
-
-
-
200.00K
Effective tax rate
-
-
-
0.56%
Other operating expenses
-
-
-
-
Net income
-23.50M
-7.93M
20.07M
35.77M
Net profit margin
-514.85%
-34.10%
36.51%
48.24%
Earnings per share
-
-
-
-
Interest and investment income
1.07M
683.00K
366.00K
323.00K
Interest expense
-2.96M
-2.91M
-2.95M
-3.00M
Net interest expenses
-1.90M
-2.22M
-2.59M
-2.67M
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.53M
-4.90M
23.74M
39.76M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps